Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology
Xinyu Liu, Hao Tang, Qingyang Zhou, Yan-Lin Zeng, Dan Chen, Hui Xu, Yue Li, Bei Tan, Jiaming Qian
Abstract
There is great heterogeneity among inflammatory bowel disease (IBD) patients in terms of pathogenesis, clinical manifestation, response to treatment, and prognosis, which requires the individualized and precision management of patients. Many studies have focused on prediction biomarkers and models for assessing IBD disease type, activity, severity, and prognosis. During the era of biologics, how to predict the response and side effects of patients to different treatments and how to quickly recognize the loss of response have also become important topics. Multiomics is a promising area for investigating the complex network of IBD pathogenesis. Integrating numerous amounts of data requires the use of artificial intelligence.